Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

By K. de Groot, N. Rasmussen, P. Bacon, J. Tervaert, C. Feighery, G. Gregorini, W. Gross, R. Luqmani, D. Jayne. Arthritis & Rheumatism, 2005

788 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis (2009, background): “The results of current randomized, controlled trials show higher relapse rates in trials that discontinued corticosteroids in the first 6 months (19) or 12 months (7), as opposed to those that, like ours, continued to administer prednisolone for 18 months and longer (2).”
EULAR recommendations for the management of primary small and medium vessel vasculitis (2008, background): “Early cessation of therapy is associated with an increased risk of relapse ( 33 ).”
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. (2014, neutral): “Alveolar hemorrhage 11 (19)† 9 (16) 20 (18)† 0.”
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis (2021, neutral): “The use of methotrexate for remission induction in this patient group is supported by more available data than other treatments (11), but azathioprine and mycophenolate mofetil can be considered.”
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, background): “Methotrexate (20–25 mg/week, oral or parenteral) can be used as an alternative to cyclophosphamide in patients with less severe disease and in those with normal renal function (23, 74, 78-85).”